Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EX 103

Next Previous
X
Search
Drug Profile

EX 103

Alternative Names: EX-103 - Guangzhou Excelmab; EX103

Latest Information Update: 16 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou Excelmab
  • Class Antineoplastics; Antirheumatics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma
  • Research Chronic lymphocytic leukaemia; Rheumatoid arthritis

Most Recent Events

  • 31 May 2024 Efficacy data from a phase I/II trial in Non-Hodgkin's lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 20 Oct 2023 Efficacy and adverse events data from phase I trial in Non-Hodgkin's lymphoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 14 Sep 2023 Guangzhou Excelmab files an BLA application in China in December 2025 (Guangzhou Excelmab pipeline september 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top